Next Article in Journal
Liposomal Taro Lectin Nanocapsules Control Human Glioblastoma and Mammary Adenocarcinoma Cell Proliferation
Next Article in Special Issue
The Concept of an Ideal Antibiotic: Implications for Drug Design
Previous Article in Journal
Ginger Straw Waste-Derived Porous Carbons as Effective Adsorbents toward Methylene Blue
Open AccessCommunication

Proof of an Outer Membrane Target of the Efflux Inhibitor Phe-Arg-β-Naphthylamide from Random Mutagenesis

1
Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, 79106 Freiburg, Germany
2
Institute of Medical Microbiology, Greifswald University Hospital, 17475 Greifswald, Germany
3
Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands
4
Faculty of Medicine, Albert-Ludwigs-University, 79085 Freiburg, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Seung Seo Lee
Molecules 2019, 24(3), 470; https://doi.org/10.3390/molecules24030470
Received: 10 January 2019 / Revised: 24 January 2019 / Accepted: 25 January 2019 / Published: 29 January 2019
(This article belongs to the Special Issue Chemical Biology of Antimicrobial Resistance)
Phe-Arg-β-naphthylamide (PAβN) has been characterized as an efflux pump inhibitor (EPI) acting on the major multidrug resistance efflux transporters of Gram-negative bacteria, such as AcrB in Eschericha coli. In the present study, in vitro random mutagenesis was used to evolve resistance to the sensitizing activity of PAβN with the aim of elucidating its mechanism of action. A strain was obtained that was phenotypically similar to a previously reported mutant from a serial selection approach that had no efflux-associated mutations. We could confirm that acrB mutations in the new mutant were unrelated to PAβN resistance. The next-generation sequencing of the two mutants revealed loss-of-function mutations in lpxM. An engineered lpxM knockout strain showed up to 16-fold decreased PAβN activity with large lipophilic drugs, while its efflux capacity, as well as the efficacy of other EPIs, remained unchanged. LpxM is responsible for the last acylation step in lipopolysaccharide (LPS) synthesis, and lpxM deficiency has been shown to result in penta-acylated instead of hexa-acylated lipid A. Modeling the two lipid A types revealed steric conformational changes due to underacylation. The findings provide evidence of a target site of PAβN in the LPS layer, and prove membrane activity contributing to its drug-sensitizing potency. View Full-Text
Keywords: PAβN; efflux pump inhibitor; random mutagenesis; lpxM (msbB); penta-acylated lipid A; permeabilizer PAβN; efflux pump inhibitor; random mutagenesis; lpxM (msbB); penta-acylated lipid A; permeabilizer
Show Figures

Graphical abstract

MDPI and ACS Style

Schuster, S.; Bohnert, J.A.; Vavra, M.; Rossen, J.W.; Kern, W.V. Proof of an Outer Membrane Target of the Efflux Inhibitor Phe-Arg-β-Naphthylamide from Random Mutagenesis. Molecules 2019, 24, 470.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop